Lixin Pharmaceutical: Shareholders and their concerted action persons reduce their holdings by 0.96%. The reduction has been completed.

On September 24, 2025, Luoxin Pharmaceutical announced that the company had received a notice from its shareholder Fang Xiubao, together with Fang Donghui and Dare Management, who are acting in concert, regarding the results of reducing their shareholding of over 5%. The company learned that the above-mentioned reduction plan has been successfully implemented. Dare Management has reduced its holdings of the company's stock by a total of 10,442,080 shares through centralized bidding from July 30, 2025, to September 24, 2025, accounting for 0.96% of the company's total share capital, or 0.97% after excluding 7,808,358 shares held in the company's buyback account.